Claudio Laudani: Efficacy and Safety of Colchicine for Secondary Prevention in Coronary Artery Disease
Claudio Laudani, Former Postdoctoral Researcher at UF Health Jacksonville, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
“Anti-inflammatory therapies are increasingly recognized as key tools to reduce major adverse cardiovascular events (MACE) in patients with coronary artery disease (CAD). Among them, colchicine has the most established and widely studied role in this setting.
However, the recent findings from clear-synergy have raised important questions regarding the efficacy and safety of colchicine for secondary prevention in CAD.
To address these uncertainties, we conducted the largest meta-analysis on colchicine to date, including 20 randomized controlled trials and 21,486 patients. We explored possible sources of heterogeneity and the influence of confounders, including clinical presentation (acute or chronic coronary syndrome), baseline medications, and the influence of colchicine dose administered, and COVID-19 pandemic. In addition, we performed trial sequential analysis to assess the conclusiveness of the results.
Overall, colchicine reduced MACE by 29%, driven by a 19% reduction in myocardial infarction and 30% reduction in revascularization, without inreasing serious adverse events. These resulted in a number needed to treat of 49 patients, and a NNT/NNH ratio of 0.5. Importantly, no significant interaction by presentation was detected, suggesting that both ACS and CCS patients may benefit from colchicine adminsitration.
However, there was a significant increase in gastrointestinal adverse events, which should be accounted when considering adding colchicine for secondary prevention of MACE, and adverse events were more likely to occur with high dose colchicine, suggesting that low-dose colchicine may achieve the best benefit/risk balance.
Finally, among possible confounders, only the COVID pandemic resulted as a possible explanation for the neutral results reported in the clear-synergy trial. Interestingly, TSA showed that results were conclusive for MACE and gastrointestinal events, further reassuring on the overall efficacy and safety of this medication for treatment of patients with CAD.”
Title: Safety and Efficacy of Colchicine across the Spectrum of Coronary Artery Disease: A Systematic Review and Meta-Analysis of 20 Randomized Trials
Authors: Claudio Laudani, Kamil Bujak, Giovanni Occhipinti, Riccardo Rinaldi, Antonino Imbesi, Jorge Sanz Sanchez, Mattia Galli, Antonio Abbate, Luis Ortega-Paz, Davide Capodanno, Dominick Angiolillo
Read the Full Article on American Society for Clinical Pharmacology and Therapeutics.
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 14, 2026, 20:53YoonHwa An: Rusfertide in Polycythemia Vera – From Clinical Benefit to Strategic Value
-
Sep 14, 2026, 20:52Andres Alberto Mercado Pompa: External Validation of Prognostic Risk Scores in Cerebral Venous Thrombosis
-
Sep 14, 2026, 20:50Balaji Kirushnan: Advancing Regional Citrate Anticoagulation in CRRT – From Experience to Implementation
-
Sep 14, 2026, 20:48Valerie Dehondt: Nutritional Anemia Is Associated With Increased Risk of Severe COPD Exacerbations
-
Sep 14, 2026, 20:46Nupur Choudhury: Exploring AI-Based Detection of Anemia Using Eye and Fingernail Images
-
Sep 14, 2026, 20:44Shamee Shastry: Chart Before You Chase – Diagnosing Drug-Induced Hemolytic Anemia
-
Sep 14, 2026, 20:43David Reiner: Blood Tests That Can Reveal Nutrition Clues
-
Sep 14, 2026, 20:40Giuseppe Biondi Zoccai: Balancing Thrombosis and Bleeding in Acute MI With Hemophilia A
-
Sep 14, 2026, 20:39Kemal Karaagac: Kounis Syndrome as a Possible Cause of Very Late Stent Thrombosis